A new pilot study (NCT03572387) is assessing the use of retinoic acid (RA) 5-AZA and ATRA in prostate cancer patients to prolong dormancy by inducing a quiescent expression signature through activation of NR2F1 [146]. The gene discussed is NR2F1; the disease is prostate cancer.